1. China Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Giant Biogene Holding Co. Ltd.

Giant Biogene Holding Co. Ltd.

HHKEX:2367
20.76
HKD
-0.22
(-1.05%)
35.07BMarket Cap
Mar 29Next Earn
Giant Biogene Holding Co. Ltd.
HKEX:2367
(Hong Kong Exchange)

Recent

price

20.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.96
1.2
1.57
3.36
3.61
5.64
5.27
- -
Revenue per Share
0.56
0.83
0.84
1.43
1.49
2.1
1.83
- -
Basic EPS, GAAP
0.55
0.76
0.59
1.11
1.45
1.83
1.29
- -
Free Cash Flow per Basic Share
- -
- -
2.57
0.52
- -
0.93
1.22
- -
Dividend per Share
1.16
0.46
1.03
2.85
4.44
7
9.4
9.4
Book Value per Share
1.15
0.45
1.02
2.84
4.44
6.99
9.4
9.4
Tangible Book Value per Share
992
992
992
703
976
982
1,047
1,051
Basic Weighted Avg Shares
957
1,190
1,552
2,364
3,524
5,539
5,519
- -
Sales/Revenue/Turnover
70.83
68.16
60.01
49.85
47.24
41.68
38.79
- -
Operating Margin (%)
18
22
24
28
34
49
82
- -
Depreciation Expense
552
826
828
1,002
1,452
2,062
1,915
- -
Net Income, GAAP
15.04
15.08
14.88
14.96
17.01
16.11
18.54
- -
Effective Tax Rate (%)
57.73
69.42
53.34
42.38
41.19
37.23
34.7
- -
Profit Margin (%)
832
110
598
2,257
3,604
5,566
8,219
8,219
Working Capital
- -
- -
- -
2
1
2
3
3
LT Debt
1,151
458
1,017
2,837
4,371
7,120
9,925
9,925
Total Equity
- -
71.83
91.81
49.89
37.28
32.98
20.2
- -
Return on Invested Capital (%)
- -
102.7
112.3
51.99
40.35
35.88
22.45
- -
Return on Capital (%)
- -
102.94
112.3
52.05
40.35
35.96
22.5
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
5
5
6
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,016
1,059
1,054
Market Capitalization
47,637
55,745
31,515

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
6,402
9,888
9,019
Cash, Cash Equivalents & STI
5,859
8,861
8,290
Accounts Receivable, Net
112
466
192
Inventories
311
441
391
Total Current Liabilities
836
2,030
800
Payables & Accruals
- -
- -
- -
ST Debt
5
5
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
91.48%
39.4%
Free Cash Flow
- -
18.94%
-24.67%
Net Income, GAAP
- -
20.2%
-7.15%
Sales/Revenue/Turnover
- -
37.71%
-0.37%
Total Cash Common Dividend
- -
- -
40.78%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3,524
2024
- -
- -
5,539
2025
- -
- -
5,519

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.49
2024
- -
- -
2.1
2025
- -
- -
1.83

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
0.93
2025
- -
- -
1.22
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Giant Biogene Holding Co., Ltd. (2367.HK) is a China-based investment holding company principally engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The company offers professional skin treatment products including functional skincare items such as recombinant collagen restoration single-use essences, precise and intensive repair series, focus creams, hydration series, regular series and collagen masks under the Comfy and Collgene brands; medical dressings like recombinant collagen dressings, repair dressings and medical skin liquid dressings; as well as rare ginsenosides technology-based functional foods and medical devices, primarily under the Comfy, Collgene, Ke Yu and SKIGIN brands. Giant Biogene Holding operates mainly within the domestic Chinese market across online platforms including Tmall, Douyin, JD.com, Xiaohongshu and Kuaishou, and offline channels encompassing approximately 1,700 public hospitals, 3,000 private hospitals and clinics, 130,000 chain pharmacies and 6,000 CS/KA stores; it was founded in 2000 with headquarters located at No. 1855, Shanglin Yuan 7th Road, Chang'an District, Xi'an, Shaanxi Province, People's Republic of China. In the first half of 2025, the company reported revenue of RMB3.11 billion, up 22.5% year-on-year, driven by new product launches including Comfy Recombinant Collagen Restoration Single-Use Essence (Collagen Stick 2.0) incorporating proprietary Type IV collagen, Comfy Precise and Intensive Repair Series with Type IV thermo-mouldable collagen, and upgraded Collgene Collagen Mask King 3.0; it expanded Comfy proprietary stores to 24 nationwide including in Hangzhou, Nanjing and Tianjin, entered Watsons Malaysia as the first Chinese functional skincare brand there, strengthened channel collaborations via summit forums and pharmacy activities, and secured top rankings in e-commerce sales during the 618 Shopping Festival such as TOP 1 on Tmall's Medical Dressing Praise List for its classic recombinant collagen dressing.